CD19 (B-Lymphocyte Marker) Antibody - With BSA and Azide
Mouse Monoclonal Antibody [Clone CVID3/429 ]
|Application ||IF, FC|
|Other Accession||930, 652262|
|Reactivity||Human, Monkey, Chimpanzee|
|Isotype||Mouse / IgG1, kappa|
|Other Names||B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12, CD19, CD19|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||CD19 (B-Lymphocyte Marker) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Assembles with the antigen receptor of B-lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.|
|Cellular Location||Membrane; Single-pass type I membrane protein|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.
Bregni, M. Siena, S., Formosa, A., Lappi, D.A., Martineau, D., Malavasi, F., Dorken, B., Bonadonna, G. and Gianni, A.M. 1989. B cell restricted saporin immunotoxins: activity against B cell lines and chronic lymphocytic leukemia cells. Blood 73: 753-76
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.